| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02796950 | Diabetes Mellitus Type 2 | Drug: Acipimox | University of Aarhus | | 2016-06-01 | 2016-06-07 |
| NCT00943059 | Diabetes Mellitus, Type 2|Cardiomyopathy, Dilated | Drug: Acipimox|Drug: Cellulosum Mycrocryst | Maastricht University Medical Center|Center for Translational Molecular Medicine | 2010-03-01 | 2013-05-13 |
| NCT01816165 | Type 1 Diabetes | Drug: Acipimox|Drug: Placebo | University of Colorado, Denver | Phase 3 | 2011-06-01 | 2017-02-16 |
| NCT01488409 | Abdominal Obesity|Insulin Resistance|Hypertriglyceridemia | Drug: Acipimox|Drug: Placebo | Massachusetts General Hospital|American Diabetes Association | Phase 2 | 2012-05-01 | 2016-02-02 |
| NCT01580813 | Type 2 Diabetes | Drug: Acipimox|Drug: Placebo | University of Colorado, Denver|VA Office of Research and Development|Pfizer | 2011-06-01 | 2017-03-16 |
| NCT01260376 | Diabetes|Obesity | Drug: Acipimox | University of Aarhus | | 2011-04-01 | 2012-09-17 |
| NCT00246402 | Insulin Resistance|Cardiovascular Diseases|Heart Diseases|HIV Infections|Hypertriglyceridemia|Hyperlipidemia | Drug: Acipimox | National Heart, Lung, and Blood Institute (NHLBI) | 2002-09-01 | 2014-05-14 |
| NCT00549614 | Heart Failure | Drug: acipimox|Drug: placebo | University of Aarhus | | 2007-10-01 | 2009-10-06 |
| NCT02782208 | Hypopituitarism|Insulin Resistance|Endocrine System Diseases|Glucose Metabolism Disorders|Metabolic Diseases|Pituitary Diseases|Brain Diseases | Drug: Acipimox|Drug: Placebo|Drug: GH substitution|Other: GH pause | University of Aarhus | | 2016-05-01 | 2016-05-20 |
| NCT02256722 | Healthy | Drug: KUC 7483 CL|Drug: Bisoprolol|Drug: Propranolol|Drug: Acipimox|Drug: Salmeterol | Boehringer Ingelheim | Phase 1 | 2005-10-01 | 2014-10-02 |
| NCT00153179 | Type 2 Diabetes Mellitus | Drug: acipimox|Drug: placebo | Brigham and Women's Hospital | Phase 1|Phase 2 | 2005-09-01 | 2013-05-30 |
| NCT01980524 | Type 2 Diabetes | Drug: acipimox | Medical University of Vienna | Phase 2|Phase 3 | 2013-10-01 | 2016-05-04 |
| NCT01209416 | Metabolism|Insulin Resistance|Hypopituitarism | Drug: Acipimox|Drug: Ghrelin|Other: Placebo | University of Aarhus | | 2012-06-01 | 2014-12-02 |
| NCT02980952 | Assessing Muscle Amino Acid Balance | Other: overfeeding|Drug: Acipimox|Other: Physical inactivity|Dietary Supplement: Eucaloric|Dietary Supplement: Placebo|Dietary Supplement: Hypercaloric | University of Exeter | | 2017-01-01 | 2016-12-01 |
| NCT00759291 | Metabolic Syndrome | Drug: acipimox|Drug: matching placebo | Brigham and Women's Hospital | Phase 2|Phase 3 | 2006-04-01 | 2016-09-14 |
| NCT02792621 | Impaired Mitochondrial Function, Muscle Performance | Dietary Supplement: Acipimox|Dietary Supplement: placebo | Royal Devon and Exeter NHS Foundation Trust|University of Exeter | 2016-11-08 | 2017-02-20 |
| NCT00449423 | Acute Heart Failure | Drug: acipimox | University of Aarhus | Phase 2 | 2007-03-01 | 2007-10-24 |
| NCT01752348 | Systemic Inflammatory Response Syndrome | Other: Endotoxin, US standard reference E.coli | University of Aarhus | | 2013-02-01 | 2014-11-24 |
| NCT01299831 | Healthy | Behavioral: 72 hour fast|Behavioral: control, 12 hour fast|Drug: Growth hormone|Drug: Olbetam | University of Aarhus|Aarhus University Hospital | 2011-01-01 | 2014-05-23 |
